TRIO is thrilled to be attending the ESMO 2024 Congress in Barcelona! We're looking forward to connecting with global leaders in oncology and sharing our latest advancements in cancer research. See the document below for details on presentations featuring TRIO data.
TRIO - Translational Research in Oncology’s Post
More Relevant Posts
-
Executive Editor - Gold Open Access Journals & Technology in Cancer Research & Treatment (IF 2.7; CiteScore 4.4). PhD in Molecular, Cell & Developmental Biology, UCLA.
While #ASCO24 is at an end, it was great following all of it on social media. If you were at ASCO and interested in potential collaborations with the journal Technology in Cancer Research & Treatment, please feel free to reach out. Thanks for sharing OncoDaily! #cancer #oncology #cancerresearch #oncodaily
I’m not at American Society of Clinical Oncology (ASCO) but still interested in connecting to discuss potential collaborations with the journal TCRT - Jennifer Lovick, PhD OncoDaily #ASCO24 #Cancer #OncoDaily #Oncology #CancerResearch
-
Reflecting on the incredible sessions and panels at #ESMOGI24, I feel more equipped than ever to tackle the challenges in GI oncology. It was an honor to exchange ideas with the best in the field and witness groundbreaking research unveiling. Here's to transforming insights into impact and forming all the new partnerships. Together, we're moving closer to a world without cancer. #RocheOncology"
-
-
Reflecting on the incredible sessions and panels at #ESMOGI24, I feel more equipped than ever to tackle the challenges in GI oncology. It was an honor to exchange ideas with the best in the field and witness groundbreaking research unveiling. Here's to transforming insights into impact and forming all the new partnerships. Together, we're moving closer to a world without cancer. #RocheOncology"
-
-
ESMO MAP 2024 begins this Wednesday, 16th October, in London, focusing on current and emerging approaches in precision oncology. I'm delighted to share that Ipsos has been chosen to present insights from our Molecular Diagnostics Monitor in the following poster presentation: Physician perceptions and the evolving landscape of Next Generation Sequencing (NGS) use across EU4+UK Please get in touch with my colleague Keerun Khela or Alessandra Franceschetti if you would like any further information, or to meet up at the event! #MAP2024 #PrecisionOncology #Oncology #Cancer #Ipsos
-
-
📚 We are pleased to announce the publication of a new scientific article detailing the clinical trial design of the EORTC-2227-BTG LEGATO study on #glioblastoma. LEGATO is the first randomised phase III trial investigating the efficacy of adding irradiation to lomustine chemotherapy at the first progression of glioblastoma. This study addresses a clinically relevant question frequently discussed in patient consultations and multidisciplinary tumour boards worldwide. ▶️ Watch the video below to learn more, and read the article here: https://lnkd.in/dz7JKj52 #CancerResearch #ClinicalTrials #Oncology #LEGATO_Horizon #HorizonEurope #EUCancerMission
Learn more about the Legato Project and the history of glioblastoma research by watching our introductory video! Legato is under the legal sponsorship of EORTC - European Organisation for Research and Treatment of Cancer and aims to define a new evidence-based standard of care for recurrent glioblastoma. Find out more about the Legato Project: https://legato-horizon.eu/ EORTC - European Organisation for Research and Treatment of Cancer Syreon Research Institute Sapienza Università di Roma Medical University of Vienna brainstrust #LEGATO_Horizon #HorizonEurope #EUCancerMission #glioblastoma #CancerResearch #ClinicalTrials #Cancer #Braintumor #Treatingcancer #Glioblastoma European Commission
-
May is National Cancer Research Month. The AACR advances the frontiers of cutting-edge cancer science through its meetings and workshops. AACR leaders worked with 12 scientific organizations and institutions to convene 30 meetings and workshops in nine countries in 2023. Learn more in the AACR Annual Impact Report: https://bit.ly/3QOy2HX #NCRM24
-
-
🧬 Hear from Emilio Yángüez, Senior Scientist in Oncology Discovery at Roche, about how new technologies are transforming cancer research and bringing us closer to delivering new treatments for patients. 🚀 With our single cell and spatial tools, complex tumor research becomes simpler, helping scientists make breakthroughs that could change the future of oncology. Want to learn more? Watch the replay of the webinar “Revolutionizing Clinical Trials,” featuring Emilio Yángüez and Emma Bell. Don't miss out on their insights! 🎥 https://lnkd.in/gGADfS8P
-
Pathologist-scientist focused on the development of the next generation of cancer biomarkers. Vice-President, Cancer Biomarker Development, AstraZeneca.
Thanks to @Diana Merino-Vega and @David Fabrizio for a fantastic talk at the @National Cancer Institute’s conference on New Frontiers in Liquid Biopsies. Innovations in ctDNA-based MRD assessment are changing precision medicine and will continue to shape the future of cancer treatment. This session expertly captured not only the role of MRD analysis, but also how this can be effectively delivered to benefit our patients. #LBx #CancerResearch #PrecisionMedicine #Oncology #CancerBiomarkerDevelopment
A huge thank you to all those who came along to the lunchtime session I co-hosted with David Fabrizio at the National Cancer Institute (NCI)'s ‘New Frontiers in Liquid Biopsies’ conference. I had a fantastic time, sharing updates and learnings on leveraging MRD insights to advance precision oncology. Great to connect with researchers and professionals from all over the world and to engage with members of the growing liquid biopsy community. #LBx #CancerResearch #PrecisionMedicine #Oncology
-
-
Attending #aacr2024? Stop by and visit my poster, Abstract 5494: Spatial organization between claudin and the tumor microenvironment in head and neck squamous cell carcinomas Presentation: April 9, 2024, 1:30 p.m. – 5:00 p.m. | Section 10 | Poster Board #16 We'll be highlighting utility of our own end to end spatial solution, MultiOmyx together with #nanostring IO360 gene expression for a comprehensive analysis of the TME of squamous cell carcinomas.
NeoGenomics is thrilled to be sharing posters at the American Association for Cancer Research® (AACR) Annual Meeting 2024. We’re proud to showcase our research in precision medicine, cancer testing, and more. To browse titles, authors and presentation details, please visit: https://lnkd.in/gE4zhhvG
-
Reflecting on the incredible sessions and panels at #ESMOGI24, I feel more equipped than ever to tackle the challenges in GI oncology. It was an honor to exchange ideas with the best in the field and witness groundbreaking research unveiling. Here's to transforming insights into impact and forming all the new partnerships. Together, we're moving closer to a world without cancer. #RocheOncology"
-
